ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2014
Maternal and fetal alternative complement pathway activation in early severe preeclampsia.
Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities.Frontiers in immunology · 2024Pooled it
- Complement factor B activation in patients with preeclampsia.Journal of reproductive immunology · 2015Trial
- The Role of Complement and CD4 T Cells in Preeclampsia and Offspring Neurodevelopment.Current opinion in physiology · 2026Article
- Exploring the plasma proteome linked to corpus luteum presence and conception mode across pregnancy stages and postpartum.Journal of assisted reproduction and genetics · 2025Article
- Endothelial Glycocalyx: The Missing Link Between Angiogenic Imbalance in Preeclampsia and Systemic Inflammation in HELLP Syndrome.Comprehensive Physiology · 2025Review
- Pregnancy outcomes in C3 glomerulopathy: a retrospective review.BMC nephrology · 2025Article
- Persistence of a Proteomic Signature After a Hypertensive Disorder of Pregnancy.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Expression of Properdin, the positive regulator of the Complement Alternative Pathway, at the fetal-maternal interface in Preeclampsia.Frontiers in immunology · 2025Article
- Identification of complement factor H variants that predispose to pre-eclampsia: A genetic and functional study.BJOG : an international journal of obstetrics and gynaecology · 2023Article
- The monosialoganglioside GM1a protects against complement attack.Cell death discovery · 2023Article
- The central role of natural killer cells in preeclampsia.Frontiers in immunology · 2023Review
- A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2022Review
- Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia.Frontiers in immunology · 2022Article
- Elevated Adipsin and Reduced C5a Levels in the Maternal Serum and Follicular Fluid During Implantation Are Associated With Successful Pregnancy in Obese Women.Frontiers in endocrinology · 2022Article
- Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy.Human immunology · 2021Review
- Diagnostic Dilemma of Thrombotic Microangiopathy in Pregnancy.Kidney international reports · 2021Article
- Adipsin of the Alternative Complement Pathway Is a Potential Predictor for Preeclampsia in Early Pregnancy.Frontiers in immunology · 2021Article
- Bioinformatics-based identification of miRNA-, lncRNA-, and mRNA-associated ceRNA networks and potential biomarkers for preeclampsia.Medicine · 2020Article
- Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) - protocol for prospective cohort study.BMC pregnancy and childbirth · 2020Article
- Normal range of complement components during pregnancy: A prospective study.American journal of reproductive immunology (New York, N.Y. : 1989) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
problemWe sought to determine whether alternative complement activation fragment Bb (Bb) levels are elevated in the maternal, fetal, and placental blood in cases of severe preeclampsia (PE) compared with normotensive controls. METHOD OF STUDY: This was a cross-sectional study of women admitted at ≥24 weeks gestation with or without severe PE. Maternal plasma was collected at the time of enrollment. Umbilical venous cord and intervillous space blood were collected at delivery. Plasma Bb levels were assessed using ELISA. Bb levels were compared between cases and controls.
resultsMedian Bb levels were higher in the maternal plasma of severe PE subjects (n = 24) than in controls (n = 20), 1.45 ± 1.03 versus 0.65 ± 0.23 μg/mL, P < 0.001. In umbilical venous plasma, Bb levels were higher in severe PE subjects (n = 15) compared with controls (n = 15), 2.48 ± 1.40 versus 1.01 ± 0.57 μg/mL, P = 0.01.
conclusionActivation fragment Bb is increased in the maternal and umbilical venous blood of cases of severe PE when compared with normotensive controls. These data provide support for alternative complement pathway involvement in the pathogenesis of severe PE and demonstrate that alternative complement activation occurs not only in the maternal but also in the fetal compartment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.